

Epilepsy key facts

For more than

30
YEARS

we have provided solutions that have helped **transform the epilepsy landscape** and **improved the lives of millions of people**

Our scientists have developed several life-changing solutions, providing individualized treatments to help people living with epilepsy.

1992

Discovery and development of **levetiracetam**¹

2000

First launch of **levetiracetam**²

2008

First launch of **lacosamide**²

2016

First launch of **brivaracetam**²

2019


First launch of **midazolam**²

Our medicines are taken by

~3
million people*

living with epilepsy²

*2021 HY results – Further facts and figures. <https://www.ucb.com/investors/Download-center>



UCB has a wealth of experience in epilepsy drug development (**>100 interventional epilepsy studies conducted**)³

OUR COMMITMENT

We are driven to **improve the lives of people living with epilepsy**, striving for symptom freedom today, anti-epileptogenic options tomorrow

HOW WILL WE ACHIEVE THIS?



Transformative medicine:

- Utilizing our experience and expertise, our **transformative science** will lead to **new treatment options** that address **specific unmet needs**, and one day, solutions that could even **impact the underlying causes of the disease**
- **Several early-stage assets in the pipeline** and a number of patient populations under assessment in our internal epilepsy 'incubator'
- **By targeting a prototype of sub-populations**, which are both identifiable and sizeable, we will develop a focused strategy to address specific unmet needs of people living with a variety of epilepsies



Health technology support:

Our long-term goal is to improve the detection, management and treatment of seizures, and we see digital health technology as a key component of epilepsy treatment and care. Our current investments and partnerships include:

- **Nile AI:** Digital care management platform to improve the coordination of all stakeholders in epilepsy care
- **Byteflies:** Commercialization of a seizure detection device
- **Helpilepsy:** A digital solution that integrates information for both patients and neurologists to manage their disease and improve patient outcomes
- **Neuro Event Labs:** A smart solution for seizure detection, combining artificial intelligence and human expertise



Sustainable value:

Over the next 5 years we will bring UCB's epilepsy treatments to more patients than ever before:

- **Potential solutions for unmet needs:** Delivery of an investigational new product as a potential solution for the rapid cessation of an ongoing seizure in patients with stereotypical prolonged seizures⁴
- **Building partnerships:** To co-create evidence that demonstrates the value of treatments; with payers on value based contracts; and with hospitals on research projects that aim to improve care pathways and patient outcomes
- **Equitable access:** We are providing improved access to quality care and medicines in low to medium income countries, through social business approaches

To learn more about UCB's commitment to epilepsy, visit www.ucb.com/UCBCares



References:

1. Gower AJ, Noyer M, Verloes R, et al. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. *Eur J Pharmacol.* 1992;222:193–203.
2. 2021 HY results - Further facts and figures. <https://www.ucb.com/investors/Download-center>.
3. UCB. Clinical Studies Index. 2021. Available at: <https://www.ucb.com/clinical-studies/Clinical-studies-index>.
4. ClinicalTrials.gov. Study Record Detail. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03478982?term=ENGAGE&cond=Epilepsy&draw=2&rank=1>.



Inspired by **patients**.
Driven by **science**.

GL-N-BR-EPOS-2100045
Date of preparation: August 2021
© UCB Biopharma SRL, 2021. All rights reserved.
Please refer to the full Prescribing Information in your country before prescribing